Imperfect adherence in real life: a prevention‐effective perspective on adherence to daily and event‐driven HIV pre‐exposure prophylaxis among men who have sex with men – a prospective cohort study in Taiwan
Open Access
- 20 May 2021
- journal article
- research article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 24 (5) , e25733
Abstract
Introduction: Both daily and event‐driven (ED) pre‐exposure prophylaxis (PrEP) have been demonstrated to be highly effective among men who have sex with men (MSM). Prevention‐effective adherence proposes that PrEP adherence should be aligned with the risk of HIV, which could be applied to both daily and ED PrEP adherence measurement. The objective of this study was to describe the relationship between the use of PrEP and sex events among the MSM PrEP users and identify factors associated with adherence among daily and ED MSM PrEP users.Methods: A multicentre, observational, prospective cohort study was conducted at three hospital‐based clinics in three urban cities of Taiwan from January 2018 to December 2019. MSM ages 18 years or older – at high risk of HIV acquisition and taking PrEP during the study period – were included in the analysis. MSM PrEP users were allowed to choose between daily and ED PrEP based on their preference. Data on sociodemographic characteristics, mental health, sexual behaviours, substance use and PrEP‐taking behaviours were collected at each visit.Results: A total of 374 MSM were included in the analysis with 1,054 visits. More than half (56%) of the PrEP users chose ED at the baseline and 150 regimen switches were reported by 21% of the participants. There was only one seroconversion documented during the study period. Most (84.2%) of the MSM PrEP users were able to adhere to PrEP during the most recent anal intercourse in the past one month. Among ED PrEP users with suboptimal adherence, the majority (81.9%) missed the pre‐coital dose. In the multivariable analysis, we found that participants who switched from daily to an ED dosing regimen were associated with poorer adherence to PrEP.Conclusions: A high level of PrEP adherence was observed among the majority of MSM in a real‐world setting. On the other hand, Taiwanese MSM switching from daily to ED dosing regimens were less likely to adhere to PrEP, suggesting that novel approaches focusing on a dosing switch would be necessary for MSM to improve their adherence to PrEP.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 108‐2636‐B‐006‐004, MOST 109‐2636‐B‐006‐004, MOST 110‐2636‐B‐006‐011)
This publication has 34 references indexed in Scilit:
- Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY TrialAIDS and Behavior, 2020
- Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort studyThe Lancet HIV, 2017
- Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialThe Lancet, 2016
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 InfectionNew England Journal of Medicine, 2015
- Defining success with HIV pre-exposure prophylaxisAIDS, 2015
- A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM‐PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South AfricaJournal of the International AIDS Society, 2014
- Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort studyThe Lancet Infectious Diseases, 2014
- Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East AfricaPLOS Medicine, 2013
- Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2013
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010